Moderna (MRNA) Stock Might Rise Further As Company Is Not Just In COVID-19 Race But In Many Others

A few months ago, the biotech company Moderna Inc. (NASDAQ: MRNA) drew investors’ attention by developing one of the most promising vaccines against COVID-19. Since the beginning of the year, MRNA shares have risen nearly 350 percent. The company currently has strong rivals who have made significant progress in developing their vaccines, so it is possible to challenge Moderna’s leadership in this area. But Moderna has a large portfolio of promising developments outside of COVID-19.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


Moderna’s mRNA-1273 vaccine is currently being developed in phase III trials involving 30,000 volunteers, half of whom are given placebo. The risk is that such studies may end at each stage if, compared to placebo, the vaccine does not show the intended efficacy or is considered to be unsafe. Because the mRNA-1273 vaccine has not previously been tested compared to placebo, investors may be afraid that the current testing stage may fail, and Moderna will lose its leadership in the prevention of COVID-19.

However, a large portfolio of promising developments is the advantage of Moderna. Thus, the organization has five candidate vaccines, five candidates in the area of immunological therapy, four rare disorder treatment approaches and two inhibitors of autoimmune diseases.

A possible Cytomegalovirus (CMV) vaccine is the most promising of these candidates. In the United States and developing nations, the virus is the leading cause of congenital disability and currently has no treatment. The Center for Disease Control and Prevention (CDC) reports that half of U.S. adults are infected with CMV by age 40 (most patients have moderate or asymptomatic symptoms). Currently, there is no approved CMV vaccine, and Moderna expects its candidate to perform phase III trials in 2021.

If efficient, the company expects to produce between $2 billion and $5 billion in revenue during peak periods.

Thus, even if Moderna is unable to fully realize its potential in the COVID-19 region, it will remain a promising investment because of a portfolio of other solutions.

Moderna Inc (MRNA) closed Thursday trading at $87.81 securing 6.51 percent gain on the day.


The Chart for Block Inc. (SQ) Stock Is Flashing Mixed Signals

In the first quarter, large investment funds expanded their...

What to Expect When Snap Inc. (SNAP) Reports Quarterly Earnings?

Snapchat, a social media platform owned by Snap Inc....

Getting Sustainable Earnings? Movado Group Inc. (MOV)

Movado Group Inc. (NYSE: MOV), the owner of the...

Future Prospects Brighter For Red Cat Holdings Inc. (RCAT) Stock

The US Army has awarded Red Cat Holdings, Inc....



Don't miss

Healthy Upside Potential: Maxar Technologies Ltd. (MAXR)

In May 25 trading, shares of space business Maxar...

Atkore Inc. (ATKR) stock: Better Than You Think

Atkore Inc. (NYSE:ATKR), a manufacturer of infrastructure, electrical, and...

Provention Bio, Inc. (PRVB) Having a Robust Premarket After Abysmal Thursday

Provention Bio, Inc. (PRVB), a clinical stage biopharmaceutical company,...

Farmmi, Inc. (FAMI) Stock Soaring in Premarket, Here’s the Reason

Farmmi, Inc. (FAMI), a company that processes and sells...

Ulta Beauty Inc. (ULTA) last month performance of -6.16% certainly makes it a sizzling prospect

Ulta Beauty Inc. (NASDAQ: ULTA) open the trading on May 26, 2022, with great promise as it jumped 7.09% to $377.96. During the day,...

The key reasons why Alset EHome International Inc. (AEI) is -95.54% away from 52-week high?

Witnessing the stock’s movement on the chart, on May 26, 2022, Alset EHome International Inc. (NASDAQ: AEI) set off with pace as it heaved...

StoneCo Ltd. (STNE) latest performance of 2.97% is not what was on cards

StoneCo Ltd. (NASDAQ: STNE) established initial surge of 2.97% at $9.71, as the Stock market unbolted on May 26, 2022. During the day, the...


Please enter your comment!
Please enter your name here